Accueil / Communiqués / UCSF First to Adopt Endomag’s Magseed as Standard of Care for Localization of Impalpable Breast Lesions

UCSF First to Adopt Endomag’s Magseed as Standard of Care for Localization of Impalpable Breast Lesions

Monday, January 23rd 2017 at 4:30pm UTC

Magseed technology guides surgeons during a breast lumpectomy to
simplify treatment and improve patient experience

CAMBRIDGE, England & SAN FRANCISCO–(BUSINESS WIRE)– Endomag, the cancer healthcare company, announced today that the
University of California, San Francisco (UCSF) has become the first US
site to adopt Magseed™ as its standard of care for localization of
impalpable breast lesions. Magseed™ is a simpler, more effective
alternative to traditional wire localization methods.

Breast cancer is the most common form of cancer in women, with 1.7
million new cases of breast cancer globally every year, and is expected
to double by 2030. Due to a rise in national screening programmes and an
increase in public awareness, breast cancer is being caught at an
earlier stage meaning that the tumors are smaller, less defined and
harder to feel, with as many as 50% of all breast tumors impalpable at
the time of diagnosis. In these cases, a technique called wire
localization is typically used by surgeons to locate the tumor.

Although widely used, wire localization commonly causes complications.
On average 1 in every 4 breast wire localizations result in cancerous
tissue being left behind and requiring additional surgery because the
wire has become dislodged between when it was implanted and when it was
removed during surgery. Additionally, there is a risk of infection due
to the wire protruding from the skin, so the placement of the wire must
be done on the same day as surgery. These issues result in unnecessary
anxiety for patients, delays to the surgical lists and fewer patients
being treated as a consequence.

Dr. Eric Mayes, CEO of Endomag noted “The wire localization
technique has remained largely the same since it was introduced over 30
years ago and it causes a lot of anxiety for patients. We wanted to
create a technique that could simplify the localization process and
improve the patient experience.”

Magseed™ is smaller than a grain of rice and can be placed into the
tumor for up to 30 days, allowing the patient to return home ahead of
surgery. Once implanted, the seed is not easily dislodged and patients
are not restricted in movement or activity. During surgery the seed is
detected with the Sentimag® probe to guide accurate removal
of the tumor and maximising the amount of healthy tissue left behind.
Unlike radioactive alternatives that involve strict regulatory oversight
and complex logistics, the Magseed™ technique can be widely adopted by
any hospital, regardless of size.

Dr. Laura Esserman (Breast Surgeon, UCSF) “We are excited to
have a set of safe, easy to use tools that will improve the efficiency
of identifying breast lesions and dramatically improve the experience of
patients and clinicians, as well as the workflow in the operating room.”

Dr. Michael Alvarado (Breast Surgeon, UCSF) “We have been
looking for a better alternative to wire localization for some time, as
the wire procedure adds additional stress for the patients on the day of
surgery and often causes delays to our operating schedule. Very early in
our evaluation of the magnetic seed technique we found that we could
avoid a same-day placement, and the surgeries could be completed in less
time, without compromising accuracy. This offers a tangible benefit to
both our clinical team and, most importantly, our patients.”


For a high res image please contact

About Endomag

Endomag is a pioneer in the use of magnetism for minimally-invasive
surgical guidance. By addressing unmet needs in availability,
affordability and workflow efficiency for surgical oncology, we support
our mission to improve the global standard of cancer care for everyone,

Founded as a spin-out from the University of Houston and the University
College London (UCL) in 2007, we continue to develop our unique clinical
platform that uses magnetic fields to power diagnostic and therapeutic
devices. The company has sales in over 30 countries worldwide and is
headquartered in Cambridge, United Kingdom.

UC Disclaimer

The information stated above was prepared by Endomag, and reflects
solely the opinion of the corporation. Nothing in this statement shall
be construed to imply any support or endorsement of Endomag, or any of
its products, by The Regents of the University of California, its
officers, agents and employees.


For Endomag
Zyme Communications
Lorna Cuddon
+44 (0)7811 996 942

Source: Endomag

Voir aussi

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Friday, January 18th 2019 at 9:05pm UTC WALTHAM, Mass.–(BUSINESS WIRE)– Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today …

Laisser un commentaire